Keeping Track: Travere’s Filspari, Chiesi’s Lamzede, Apellis’ Syfovre Headline US FDA Approvals; CRLs For Phathom, Biocon

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Keeping Track Feature image
Busy week included approval of Apellis’ age-related macular degeneration treatment and an application for the first China-developed biosimilar in the US.

The US Food and Drug Administration closed out last week with the approvals of two novel agents for rare diseases, Travere Therapeutics, Inc.'s Filspari for IgA nephropathy and Chiesi Global Rare Diseases’ Lamzede in alpha-mannosidosis.

Filspari and Lamzede bring the Center for Drug Evaluation and Research’s novel agent count for 2023 to seven approvals.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America